These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22748658)

  • 1. Clinical trials with immunotherapy for high-grade glioma.
    Ruzevick J; Jackson C; Phallen J; Lim M
    Neurosurg Clin N Am; 2012 Jul; 23(3):459-70. PubMed ID: 22748658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for glioma: promises and challenges.
    Han SJ; Zygourakis C; Lim M; Parsa AT
    Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of cellular immunotherapy for patients with glioblastoma.
    Vauleon E; Avril T; Collet B; Mosser J; Quillien V
    Clin Dev Immunol; 2010; 2010():. PubMed ID: 20953324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cellular immunotherapy for malignant glioma].
    Okamoto Y; Yamashita J
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
    Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.
    Bregy A; Wong TM; Shah AH; Goldberg JM; Komotar RJ
    Cancer Treat Rev; 2013 Dec; 39(8):891-907. PubMed ID: 23790634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy for malignant glioblastoma].
    Nose T; Nakagawa K
    No Shinkei Geka; 1995 Mar; 23(3):195-206. PubMed ID: 7700486
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy in human glioblastoma.
    Szabo AT; Carpentier AF
    Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.
    Zhang Z; Tang LL; Zhan RY; Tong Y; Yao HP; Du LA
    J Zhejiang Univ Sci; 2004 Oct; 5(10):1298-303. PubMed ID: 15362204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
    Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
    J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
    Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
    Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
    J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunotherapeutic strategies for the treatment of malignant gliomas.
    Nagasawa DT; Fong C; Yew A; Spasic M; Garcia HM; Kruse CA; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):481-95. PubMed ID: 22748660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental studies on the antitumor activity of glioma-infiltrating lymphocytes against autologous glioma].
    Li Y
    Zhonghua Yi Xue Za Zhi; 1992 May; 72(5):284-6, 319. PubMed ID: 1327462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive cell transfer therapy for malignant gliomas.
    Ishikawa E; Takano S; Ohno T; Tsuboi K
    Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
    Thomas C; Schober R; Lenard HG; Lumenta CB; Jacques DB; Wechsler W
    Neuropediatrics; 1992 Jun; 23(3):123-5. PubMed ID: 1641079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.